OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 08:00:24 13/06/2024 BST | ||
| 14.55 EUR | +0.07% |
|
| Current month | +19.28% | ||
| 1 month | +48.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 14.55 | +0.07% |
| 12/06/24 | 14.54 | -4.28% |
| 11/06/24 | 15.19 | -0.65% |
| 10/06/24 | 15.29 | -0.71% |
| 07/06/24 | 15.4 | +3.43% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 08:00 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GX9B68 |
| ISIN | DE000GX9B682 |
| Date issued | 06/09/2022 |
| Strike | 320.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.41 € |
|---|---|
| Lowest since issue | 0.219 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475.8
USD
Average target price
463.4
USD
Spread / Average Target
-2.60%
- Stock Market
- Certificates
- Certificat